Related references
Note: Only part of the references are listed.The emerging role of immune checkpoint based approaches in AML and MDS
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML
Aditi Shastri et al.
LANCET HAEMATOLOGY (2018)
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
Moshe Mittelman et al.
LANCET HAEMATOLOGY (2018)
Good news for patients with myelodysplastic syndromes and thrombocytopenia
Moshe Mittelman
LANCET HAEMATOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker et al.
LANCET ONCOLOGY (2017)
ELTROMBOPAG IN COMBINATION WITH AZACITIDINE FOR FIRST-LINE TREATMENT OF MDS PATIENTS WITH THROMBOCYTOPENIA: THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE III, SUPPORT STUDY
M. Dickinson et al.
LEUKEMIA RESEARCH (2017)
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
Antonio Almeida et al.
LEUKEMIA RESEARCH (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients
Devendra K. Hiwase et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Graphical representation of clinical outcomes for patients with myelodysplastic syndromes
David P. Steensma
LEUKEMIA & LYMPHOMA (2016)
Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?
Charlotte K. Brierley et al.
CURRENT OPINION IN HEMATOLOGY (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Thrombopoiesis-stimulating agents and myelodysplastic syndromes
Charlotte K. Brierley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension
Jonathan D. Licht
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies
Eric Padron et al.
CURRENT OPINION IN HEMATOLOGY (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
M. G. Della Porta et al.
LEUKEMIA (2015)
Myelodysplastic Syndromes: Diagnosis and Treatment
David P. Steensma
MAYO CLINIC PROCEEDINGS (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
How we treat higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
BLOOD (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
David P. Steensma et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
How we treat lower-risk myelodysplastic syndromes
Pierre Fenaux et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes
Alexander E. Sherman et al.
LEUKEMIA RESEARCH (2013)
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Amanda Cashen et al.
ANNALS OF HEMATOLOGY (2012)
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS
Aaron T. Gerds et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience
Murat Ozbalak et al.
HEMATOLOGICAL ONCOLOGY (2012)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Subcutaneous or Intravenous Administration of Romiplostim in Thrombocytopenic Patients With Lower Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
CANCER (2011)
Targeting Immune Dysregulation in Myelodysplastic Syndromes
Matthew J. Olnes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hematopoietic Growth Factors in Myelodysplastic Syndromes
David P. Steensma
SEMINARS IN ONCOLOGY (2011)
Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
Elias Jabbour et al.
CANCER (2010)
The Epidemiology of Myelodysplastic Syndromes
Mikkael A. Sekeres
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey
David P. Steensma et al.
LEUKEMIA RESEARCH (2008)
Management of thrombocytopenia in bone marrow failure: A review
Michael E. Salacz et al.
JOURNAL OF PALLIATIVE MEDICINE (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome
G Chan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
